中国经济网北京7月21日讯 华骐环保(300929.SZ)7月18日披露关于控股股东的一致行动人减持计划 的预披露公告称，公司近日收到公司控股股东的一致行动人王爱斌、胡一强出具的《关于股份减持计划 的告知函》。 在公告披露之日起15个交易日后的3个月内，持有公司股份3,610,422股(占本公司总股本比例2.73%) 的股东王爱斌计划以集中竞价交易方式减持本公司股份不超过1,312,500股，即减持比例不超过公司总股 本的0.99%；持有公司股份35,200股(占本公司总股本比例0.03%)的股东胡一强计划以集中竞价交易方式 减持本公司股份不超过8,800股，即减持比例不超过公司总股本的0.01%。上述股东通过集中竞价交易方 式减持，在任意连续90个自然日内减持股份数量不超过公司股份总数的1%。。 华骐环保表示，王爱斌、胡一强属于公司控股股东的一致行动人，本次减持计划实施不会导致公司 控制权发生变更，不会对公司治理结构、股权结构及持续性经营产生影响。 华骐环保于2021年1月20日在深交所创业板上市，发行数量为2065万股，发行价格为13.87元/股， 保荐机构为国元证券股份有限公司，保荐代表人为朱焱武、刘依 ...

中国经济网北京7月21日讯近日，中国证监会北京证监局发布了关于对北京永安财富投资基金管理有限 公司(下称"永安基金")采取出具警示函行政监管措施的决定。 经查，永安基金存在管理、运用私募基金财产，未能恪尽职守，履行诚实信用、谨慎勤勉的义务。上述 行为违反了《私募投资基金监督管理暂行办法》(下称《暂行办法》)第四条第一款之规定。依据《暂行 办法》第三十三条之规定，北京证监局决定对该公司采取上述监管措施。 相关法规： 《私募投资基金监督管理暂行办法》第三十三条：私募基金管理人、私募基金托管人、私募基金销售机 构及其他私募服务机构及其从业人员违反法律、行政法规及本办法规定，中国证监会及其派出机构可以 对其采取责令改正、监管谈话、出具警示函、公开谴责等行政监管措施。 《私募投资基金监督管理暂行办法》第四条：私募基金管理人和从事私募基金托管业务的机构(以下简 称私募基金托管人)管理、运用私募基金财产，从事私募基金销售业务的机构(以下简称私募基金销售机 构)及其他私募服务机构从事私募基金服务活动，应当恪尽职守，履行诚实信用、谨慎勤勉的义务。私 募基金从业人员应当遵守法律、行政法规，恪守职业道德和行为规范。 以下为原文： ...

Group 1 - The company Kailda (688255.SH) has disclosed a voluntary announcement regarding its performance forecast for the first half of 2025, expecting a net profit attributable to shareholders of between 1.97 million and 2.56 million yuan, a decrease of 21.54 million to 20.95 million yuan compared to the same period last year, representing a year-on-year decline of 91.62% to 89.11% [1] - The company anticipates a net profit attributable to shareholders after deducting non-recurring gains and losses to be between -3.13 million and -2.54 million yuan, a decrease of 21.86 million to 21.27 million yuan compared to the same period last year, indicating a year-on-year decline of 116.71% to 113.56% [1] Group 2 - Kailda's initial public offering raised a total of 924 million yuan, with a net amount of 835 million yuan, exceeding the original plan by 518 million yuan [2] - The company planned to raise 317 million yuan for projects including the construction of an intelligent welding robot production line and an assembly testing laboratory, as well as to supplement working capital [2] - The total issuance costs for the IPO amounted to 88.51 million yuan, with the underwriting fees for the sponsor, Shenwan Hongyuan Securities, totaling 60.99 million yuan [2]

在充满不确定性的资本市场中，工银瑞信基金以20年的发展历程，践行了"稳健创造持久财富"的初心。 据国泰海通证券发布的基金公司权益类资产业绩排行榜单数据，截至2025年上半年末，工银瑞信旗下主 动权益基金近五年绝对收益，在13家权益类大型公司中名列第一；近两年与近五年的超额收益率，也在 13家权益类大型公司中位居第一。 这份跨越周期的成绩单，离不开工银瑞信基金深度融合的投研生态体系赋能。宏观策略的望远镜、行业 研究的显微镜、投研团队的分工协作共筑三维坐标，为基金经理提供精准导航。而盛震山，这位深耕价 值投资的舵手，正是依托这套系统化平台，在资本浪潮中开辟独特的逆向航路。 平台筑基：战略母港的精密协同 工银瑞信的投研体系如同精密运转的钟表，每个齿轮的咬合都关乎整体效能。秉持"稳健投资、价值投 资、长期投资、责任投资、绿色投资"理念，工银瑞信基金坚持集体决策与个体决策相结合，不断优化 工作流程、机制，促进投研充分互动、研究成果共享，持续提升决策机制的规范性与效率。 在团队化、平台化、一体化的投研管理体系下，工银瑞信基金逐步建立起一支优秀的投研团队，通过平 台化架构充分释放团队合力，实现投研一体化、相互促进。得益于研 ...

Core Viewpoint - Kanghua Biotech (300841.SZ) has resumed trading with a stock price drop of 8.35% to 66.00 yuan following the announcement of a significant share transfer agreement that will change the company's control [1][2]. Share Transfer Agreement - On July 18, 2025, Kanghua Biotech signed a share transfer agreement involving its controlling shareholder Wang Zhentao and other major shareholders, transferring a total of 28.46638 million shares to Shanghai Wankexin Biotechnology Partnership, accounting for 21.9064% of the total share capital after excluding repurchased shares [1][2][4]. - Following the transfer, Wang Zhentao will delegate voting rights for 10.503517 million shares (8.0829% of total shares) to Wankexin, resulting in Wankexin holding 29.9893% of voting rights, thus changing the controlling shareholder from Wang Zhentao to Wankexin, with no actual controller thereafter [2][3]. Financial Details of the Transaction - The total consideration for the share transfer is 1.851088682 billion yuan, with a per-share price of 65.0266 yuan. The payment will be made from Wankexin's own and raised funds [4][8]. - Wankexin plans to finance the acquisition through a combination of self-funding (700 million yuan) and bank loans (1.15 billion yuan), with a loan term of no less than 7 years [4][8]. Company Performance - Kanghua Biotech has experienced a decline in both revenue and net profit over the past three years, with 2024 revenue reported at 1.432 billion yuan, down 9.23% from 2023, and net profit at 398.65 million yuan, down 21.71% [10][11]. - In Q1 2025, the company reported a revenue of 138 million yuan, a significant drop of 55.70% year-on-year, and a net profit of 2.07 million yuan, down 86.15% [12][10]. Shareholder Structure - The major shareholders prior to the transaction included Wang Zhentao, Aokang Group, and Jinan Kangyue Qiming Investment Partnership, with Aokang Group holding 12.5478% and Wang Zhentao holding 10.7772% [3][5]. - Post-transaction, Wankexin will become the largest shareholder, significantly altering the ownership landscape of Kanghua Biotech [2][3].

Core Insights - The third China International Supply Chain Promotion Expo showcased L'Oréal's commitment to innovation and development in the beauty supply chain [1][2] - L'Oréal emphasizes the importance of collaboration with local partners to enhance operational efficiency and sustainability in China [1][2] Group 1: Company Strategy - L'Oréal's North Asia and China Public Affairs President highlighted the expo as a platform for deep dialogue and joint innovation with supply chain partners [1] - The company launched its first smart operations center in Suzhou, capable of processing over 7,000 direct-to-consumer orders per hour, reflecting its focus on emotional value for consumers [1] - L'Oréal has established strong connections with over 1 billion Chinese consumers through its 32 brands, optimizing its local supply chain system [1] Group 2: Supply Chain Collaboration - L'Oréal collaborates with over 1,600 local suppliers, enabling them to expand their business into markets like South Korea, Japan, France, and the United States [1] - The company aims to drive innovation among small and medium-sized enterprises in the supply chain, turning local innovations into global solutions [1] - A strategic cooperation agreement was signed with the China Barcode Technology and Application Association to enhance the application guidelines for beauty product barcodes, promoting traceability in the global supply chain [1] Group 3: Market Position - China is identified as L'Oréal's second-largest market and a strategic hub for innovation, with the company committed to continuous investment in the region [1][2] - The company believes that the future of the beauty industry relies on collaborative efforts rather than isolated initiatives, aiming for a sustainable and inclusive beauty ecosystem [2]

Core Viewpoint - Changhong High-Tech (605008.SH) has announced a plan to acquire 100% equity of Guangxi Changke through a combination of issuing shares, convertible bonds, and cash payments, while also raising supporting funds from specific investors [1][2]. Group 1: Acquisition Details - The acquisition involves three parties: Hainan Dingheng, Ningbo Dingke, and Ningbo Dingao, all controlled by Tao Chunfeng, who holds a total of 100% equity in Guangxi Changke [2]. - The final transaction price for the acquisition will be determined based on an asset evaluation report from a qualified institution, and the price is yet to be finalized [1][2]. - The acquisition does not change the company's controlling shareholder or actual controller, maintaining the status quo post-transaction [2]. Group 2: Financial Performance of Guangxi Changke - Guangxi Changke's projected revenues for 2023, 2024, and the first half of 2025 are 667.80 million, 1.0173 billion, and 807.90 million yuan respectively, with net profits of -33.60 million, -79.08 million, and 34.91 million yuan [2][3]. - The company has experienced significant losses due to high R&D investments and the gradual ramp-up of production lines for specialty resin products [3]. Group 3: Fundraising and Investment Plans - The company has decided to terminate its plan for a simplified procedure to issue shares to specific investors for 2024, citing ongoing major asset restructuring and fundraising efforts [4]. - The previous plan aimed to raise up to 300 million yuan for various projects, including a TPE black masterbatch technology upgrade and working capital [5][6]. - The total investment for the projects outlined in the fundraising plan was 457.90 million yuan, with specific allocations for each project [6].

Core Viewpoint - The major shareholder of Rundu Co., Ltd. plans to reduce their stake in the company, which may impact the stock performance but will not change the control structure of the company [1][2]. Shareholder Reduction Plan - Li Xi, the controlling shareholder, holds 100,865,992 shares, representing 30.12% of the total share capital, and plans to reduce holdings by up to 10,046,797 shares (3.00% of total shares) within three months from August 11, 2025, to November 10, 2025 [1][2]. - The reduction will occur through centralized bidding and block trading, with a maximum of 3,348,932 shares (1%) via centralized bidding and 6,697,865 shares (2%) via block trading [1]. Financial Performance - Rundu Co., Ltd. expects a net loss attributable to shareholders of between 30 million and 39 million yuan for the first half of 2025, compared to a profit of 37.80 million yuan in the same period last year, representing a decline of 179.36% to 203.17% [2][3]. - The net profit after excluding non-recurring gains and losses is projected to be a loss of 38 million to 46 million yuan, down from a profit of 31.48 million yuan in the previous year, indicating a decline of 220.72% to 246.13% [2][3]. - Basic earnings per share are expected to be a loss of 0.09 to 0.12 yuan, compared to a profit of 0.11 yuan in the previous year [3].

本次拟减持的原因为自身资金安排；本次拟减持的股份来源为公司首次公开发行前取得的股份。 中国经济网北京7月21日讯 惠云钛业(300891.SZ)上周五披露了关于控股股东、实际控制人及一致行 动人减持股份预披露公告。 据惠云钛业公告，公司于近日收到控股股东、实际控制人、董事长钟镇光和一致行动人美国万邦有 限公司(以下简称"美国万邦")出具的《减持计划告知函》。 钟镇光和一致行动人美国万邦计划在公告披露之日起15个交易日后的3个月内以集中竞价和大宗交 易方式合计减持公司股份不超过11,920,900股(占公司总股本的2.9802%，占公司总股本剔除回购专用账 户中股份后的3.0000%)。 其中以集中竞价方式合计减持不超过3,973,662股(占公司总股本的0.9934%，占公司总股本剔除回购 专用账户中股份后的1.0000%)，其中钟镇光以集中竞价方式减持不超过1,402,900股(占公司总股本的 0.3507%，占公司总股本剔除回购专用账户中股份后的0.3530%)，美国万邦以集中竞价方式减持不超过 2,570,762股(占公司总股本的0.6427%，占公司总股本剔除回购专用账户中股份后的0.6470%)；美 ...

Group 1 - Tianli Lithium Energy disclosed a pre-announcement regarding shareholder share reduction, with Henan Fude High-tech New Material Venture Capital Fund planning to reduce 5,400,000 shares, accounting for 4.55% of the total share capital [1] - The reason for the share reduction is that the operating period of Fude Fund is about to expire, necessitating the liquidation of its holdings [1] - The share reduction will not lead to a change in the company's control or significantly impact its governance structure or ongoing operations [1] Group 2 - Tianli Lithium Energy raised a total of 173,850.00 million yuan from its initial public offering, with a net amount of 155,033.16 million yuan, exceeding the original plan by 71,387.50 million yuan [2] - The company initially planned to raise 83,645.66 million yuan for projects related to ternary cathode materials in Huai Bei and Xinxiang [2] - The total issuance costs for the IPO amounted to 18,816.84 million yuan, with underwriting fees constituting 16,315.75 million yuan [2]